Build A Bear Workshop Inc vs Moderna, Inc. — how do they compare? Build A Bear Workshop Inc trades at $32.95 (market cap $412.61M), while Moderna, Inc. trades at $67.13 (market cap $26.76B). The key difference: Moderna, Inc. is far larger — about 64.9× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.8% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| BBW | MRNA | |
|---|---|---|
Market Cap | $412.61M | $26.76B |
Sector | Consumer Cyclical | Health |
52-Week High | $75.85 | $81.80 |
52-Week Low | $29.84 | $22.36 |
Enterprise Value | $512.05M | $22.85B |
Dividend Yield | 2.8% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.
While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.
Trailing returns across standard periods
Latest headlines on both assets
Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.
Read more on BBW →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →